ProMIS Neurosciences Inc (PMN)

Currency in USD
3.210
-0.100(-3.02%)
Closed·
3.270+0.060(+1.87%)
·
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.1003.390
52 wk Range
2.78027.400
Key Statistics
Prev. Close
3.21
Open
3.12
Day's Range
3.1-3.39
52 wk Range
2.78-27.4
Volume
145.57K
Average Volume (3m)
157.99K
1-Year Change
-64.6378%
Book Value / Share
4.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
42.222
Upside
+1,215.33%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

ProMIS Neurosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 42.222
(+1,215.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy18.00+460.75%-Maintain16-10-2026
H.C. Wainwright
Buy18.00+460.75%-Maintain12-10-2026
Guggenheim
Buy100.00+3,015.26%69.00Maintain14-08-2026
Guggenheim
Buy69.00+2,049.53%35.00Maintain29-07-2026
Chardan
Buy33.00+928.04%20.00Maintain28-07-2026

ProMIS Neurosciences Inc Earnings Call Summary for Q3/2026

  • ProMIS Q3 2026 net loss narrowed to $8.2M ($0.89/share) vs. $11.6M ($5.93/share) YoY; cash position of $44.1M expected to fund ops through 2027.
  • R&D spending fell 32% YoY to $6.7M as PRECISE-AD Alzheimer's trial nears completion; all patient visits expected to conclude in Q4 2026.
  • Unblinded 12-month PRECISE-AD data due Q1 2027; interim results showed no ARIA-E cases and mild ARIA-H rates, supporting safety profile claims.
  • Management planning End-of-Phase II FDA meeting post-readout and designing registration study; developing subcutaneous formulation of PMN310 in parallel.
  • CEO Warma targets 15-20% slowing of decline as meaningful efficacy signal; stock down 49% YTD amid high volatility, trading at $3.48 in regular session.
Last Updated: 13-11-2026, 04:06 am
Read Full Transcript

Earnings

Latest Release
12-11-2026
EPS / Forecast
-0.89 / -0.18
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PMN Income Statement

Compare PMN to Peers and Sector

Metrics to compare
PMN
Peers
Sector
Relationship
P/E Ratio
−0.7x−1.7x−0.2x
PEG Ratio
−0.01−0.300.00
Price/Book
0.7x1.8x2.6x
Price / LTM Sales
-2.0x2.7x
Upside (Analyst Target)
-394.8%68.5%
Fair Value Upside
Unlock−2.0%11.5%Unlock

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
485.000.01%1.61K
Other Institutional Investors
10.24M99.99%33.90M
Public Companies & Retail Investors
0.000.00%0.00
Total
10.24M100.00%33.9M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.14.42%12,92,7574,279
Ally Bridge Group10.59%9,50,0793,145

FAQ

What Is the ProMIS Neurosciences (PMN) Share Price Today?

The ProMIS Neurosciences share price today is 3.210.

What is the current ProMIS Neurosciences (PMN) share price and day range?

As of 18-11-2026, the ProMIS Neurosciences share price is 3.210, with a previous close of 3.210. The share price has ranged from 3.100 to 3.390 today, while the 52-week range spans from 2.780 to 27.400.

What Is the ProMIS Neurosciences Market Cap?

As of today, ProMIS Neurosciences market cap is 28.790M.

What Is the ProMIS Neurosciences (PMN) Share Price Target?

The average 12-month share price target for ProMIS Neurosciences is 42.222, with a high estimate of 99.59832344 and a low estimate of 14.93398533. 7 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +1,215.33% Upside potential.

What Is ProMIS Neurosciences's Earnings Per Share (TTM)?

The ProMIS Neurosciences EPS (TTM) is -5.65.

From a Technical Analysis Perspective, Is PMN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does ProMIS Neurosciences Trade On?

ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ProMIS Neurosciences?

The stock symbol for ProMIS Neurosciences is "PMN."

How Many Times Has ProMIS Neurosciences Stock Split?

ProMIS Neurosciences has split 2 times.

How Many Employees Does ProMIS Neurosciences Have?

ProMIS Neurosciences has 11 employees.

What Is the PMN After Hours Price?

PMN's last after hours stock price is 3.270, the stock has changed by 0.060, or 1.870%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.